Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00411528. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Multicenter Phase II Trial of Patupilone (EPO906) Plus Prednisone Versus Docetaxel Plus Prednisone in Patients With Metastatic Hormone Refractory Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study is to assess the response of patupilone plus prednisone compared to docetaxel plus prednisone on prostate specific antigen (PSA) in patients with metastatic hormone refractory prostate cancer. Additionally, this study will assess the response on measureable disease and the effects on patient-reported outcomes.
Study identification
- NCT ID
- NCT00411528
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 185 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2006 (Type not available)
- Primary completion
- Sep 2012 (Actual)
- Completion
- Sep 2012 (Actual)
- Last update posted
- Dec 17, 2020
2006 – 2012
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Diego Dept of Moores Cancer Center | La Jolla | California | 92093-0658 | — |
| University of Colorado Dept. of Univ. of Colorado | Aurora | Colorado | 80045 | — |
| Norwalk Hospital | Norwalk | Connecticut | 06856 | — |
| Georgetown University/Lombardi Cancer Center Dept.of Lombardi Cancer Center | Washington D.C. | District of Columbia | 20007-2197 | — |
| MD Anderson Cancer Center - Orlando CEPO906A2229 | Orlando | Florida | 32806 | — |
| H. Lee Moffitt Cancer Center/University of South Florida Department of Genitourology | Tampa | Florida | 33612 | — |
| Palm Beach Cancer Institute | West Palm Beach | Florida | 33401 | — |
| NorthWest Georgia Oncology Centers Marietta Center | Marietta | Georgia | 30060 | — |
| University Chicago Hospital StudyCoordinator:CEPO906A2229 | Chicago | Illinois | 60637 | — |
| Queens Cancer Center of Queens Hospital | Jamaica | New York | 11432 | — |
| Oregon Health & Science University StudyCoordinator:CEPO906A2229 | Portland | Oregon | 97239 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00411528, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 17, 2020 · Synced Nov 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.